Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Justin Kline, MD, Aaron P. Rapoport, MD, Adam M. Petrich, MD, Kenneth S. Cohen, MD, Sachdev P. Thomas, MD, Sreenivasa Nattam, MD, Krishna Rao, MD, Bethany Sleckman, MD, Walter Stadler, MD, Theodore Karrison, PhD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4147.

https://doi.org/10.1182/blood.V128.22.4147.4147

Published: 2016

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Fátima de la Cruz Vicente, Estrella Carrillo Cruz, María Solé Rodríguez, Ana Marín Niebla, Eduardo Ríos Herranz, María Luz Martino Galiana, Jose Falantes González, Isabel Montero Cuadrado, Jose González Campos, Ildefonso Espigado Tocino, Jose A Pérez-Simón

Blood (2013) 122 (21): 5087.

https://doi.org/10.1182/blood.V122.21.5087.5087

Published: 2013

Journal Articles

Outcomes Of Colonoscopies In Patients With Bleeding Disorders

Ashley N Cobb, BA, Amy Eckerman, RN, Rajiv K Pruthi, MBBS

Blood (2013) 122 (21): 1115.

https://doi.org/10.1182/blood.V122.21.1115.1115

Published: 2013

Journal Articles

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Lia Gore, MD, Margaret E. Macy, M.D., Francoise Mechinaud, MD, Aru Narendran, MD, PhD, Frank Alvaro, MD, Carola A.S. Arndt, MD, Phillip Barnette, MD, Jessica Boklan, MD, Todd Cooper, DO, Laura Martin, MD, W Tcheng, MD, Peter Tarassoff, MD, Mark M Jones, MD, Soheil Meshinchi, MD, PhD, Robert J. Arceci, MD, PhD

Blood (2012) 120 (21): 1517.

https://doi.org/10.1182/blood.V120.21.1517.1517

Published: 2012

Journal Articles

R-CHOP Every Two Weeks with Pegylated Filgastrim Support for the Treatment of CD20+ Aggressive Non Hodgkin's Lymphoma: Feasibility of Delivery On Time.

Shatha Y. Farhan, MD, Tim Kasunic, MD, George Divine, PhD, Philip Kuriakose, MD, Nalini Janakiraman, MD

Blood (2009) 114 (22): 4773.

https://doi.org/10.1182/blood.V114.22.4773.4773

Published: 2009

Journal Articles

Hemophagocytic Lymphohistiocytosis (HLH) in Adults Should Be Treated through Intensive Immune Suppression: 2 Case Reports

Shuangfeng Xie, Songmei Yin, BA, Liping Ma, Danian Nie, Yiqing Li, Xiuju Wang, Dongmei Liang

Blood (2008) 112 (11): 4658.

https://doi.org/10.1182/blood.V112.11.4658.4658

Published: 2008

Journal Articles

Long-Term Clinical Follow-Up and Safety/Toxicity Analysis in 3 X-CGD Patients Treated by Gene Therapy and Non-Myeloablative Conditioning.

Marion G. Ott, MD, Manfred Schmidt, PhD, Stefan Stein, PhD, Kerstin Schwarzwaelder, Ulrich Siler, PhD, Ulrike Koehl, PhD, Klaus Kuehlcke, PhD, Andrea Schilz, PhD, Christoph v. Kalle, PhD, Dieter Hoelzer, MD, Reinhard Seger, MD, Manuel Grez, PhD

Blood (2006) 108 (11): 199.

https://doi.org/10.1182/blood.V108.11.199.199

Published: 2006

Journal Articles

BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features.

Ruben Niesvizky, MD, K. Pekle, RN, ANPC, U. Gelbshtein, F. Zafar, RPAC, S. Ostrow, MD, R. Pearse, MD, PhD, H. Cho, MD, PhD, J. Tepler, MD, S. Ely, MD, R. Lent, PhD, D. Jayabalan, T. Shore, MD, J. Harpel, MD, PhD, M. Schuster, MD, L. Lyons, R. Furman, MD, J. Leonard, MD, S. Chen-Kiang, PhD, M. Coleman, MD

Blood (2005) 106 (11): 642.

https://doi.org/10.1182/blood.V106.11.642.642

Published: 2005

Journal Articles

Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).

S. Vincent Rajkumar, MD, Suzanne R. Hayman, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Antje Hoering, PhD, Susan M. Geyer, PhD, Steven R. Zeldenrust, MD, PhD, Philip R. Greipp, MD, Rafael Fonseca, MD, John A. Lust, MD, PhD, Stephen J. Russell, MD, PhD, Robert A. Kyle, MD, Thomas E. Witzig, MD, Morie A. Gertz, MD

Blood (2004) 104 (11): 331.

https://doi.org/10.1182/blood.V104.11.331.331

Published: 2004

NARROW

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Outcomes Of Colonoscopies In Patients With Bleeding Disorders

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

R-CHOP Every Two Weeks with Pegylated Filgastrim Support for the Treatment of CD20+ Aggressive Non Hodgkin's Lymphoma: Feasibility of Delivery On Time.

Hemophagocytic Lymphohistiocytosis (HLH) in Adults Should Be Treated through Intensive Immune Suppression: 2 Case Reports

Long-Term Clinical Follow-Up and Safety/Toxicity Analysis in 3 X-CGD Patients Treated by Gene Therapy and Non-Myeloablative Conditioning.

BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features.

Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only